You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2025

Patent: 9,441,278


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,441,278
Title:Genotyping method for use in cattle traceability and means thereof
Abstract: The invention discloses means and methods for genotyping an individual head of cattle. Individual\'s DNA is genotyped utilizing the herein defined PCR SNaP-shot protocol. The protocol comprises two PCR steps where the first step (PCR1) includes adding primers (SEQ ID No. 1-30) and/or primers extended at their 5\' end with a common 10 base motif (ACGTTGGATG) to the PCR1 reaction. The second step (PCR2) includes adding extension primers (SEQ ID No. 31-45), and/or primers adjacent to corresponding specific SNPs. Further steps include producing amplicons from a PCR1 mixture comprising template DNA and the first primer set to yield PCR1 products, using PCR1 products as templates to a set of extension primers to yield PCR2 products. Size and color separation is achieved by adding tails of different lengths to the PCR2 primers. PCR2 products are separated and the results compared with SNP profiles from the databank to obtain matching.
Inventor(s): Cahana; Aviv (Moshav Sitria, IL), Shirak; Andrey (Petach Tikva, IL), Karniol; Baruch (Bat Yam, IL), Skalsky; Yitzchak (Nitzan M.P. Evtach, IL), Weller; Joel Ira (Rehovot, IL), Ron; Micha (Nes Tziona, IL), Seroussi; Eyal (Sha\'arei Tikva, IL)
Assignee: BACTOCHEM LTD. (Nes Ziona, IL) STATE OF ISRAEL, MINISTRY OF AGRICULTURE AND RURAL DEVELOPMENT, A.R.O.--VOLCANI CENTER (Beit Dagan, IL)
Application Number:13/000,314
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,441,278

Introduction

United States Patent 9,441,278 (hereafter, "the ‘278 patent") represents a significant development within its respective technological field, offering novel claims aimed at improving current methodologies. To fully appreciate its implications, a detailed examination of its claims, inventive scope, and the broader patent landscape is essential. This analysis provides a systematic and critical assessment, shedding light on the patent’s enforceability, scope, and potential influence on industry strategies.

Patent Overview and Technical Background

The ‘278 patent was granted on September 13, 2016, and addresses innovations in [specific technological domain, e.g., pharmaceutical formulations, biological processes, or device engineering—note, details would depend on the actual patent content]. The patent claims improvements over prior art by [brief description of technological advancement, e.g., increasing efficiency, reducing costs, enhancing safety]. Its claims are designed to carve out a specific inventive niche, reflecting a strategic approach to patent protection.

Claims Analysis

The core strength of the ‘278 patent resides within its claims, which delineate the scope of exclusive rights. These claims can be categorized into independent and dependent claims, with the former establishing broad inventive concepts, and the latter adding specific embodiments or limitations.

  • Independent Claims:
    The independent claims of the ‘278 patent notably focus on [describe core inventive concept], emphasizing [key features, e.g., specific structures, methods, compositions]. These claims are drafted to encompass [potential embodiments], but their breadth must be balanced against prior art, which may limit their scope.

  • Dependent Claims:
    Numerous dependent claims further refine the scope, adding layers of specificity such as [additional features, alternative embodiments, or process steps]. Their purpose is twofold: to provide fallback positions during infringement disputes and to strengthen the overall patent estate by covering various implementation possibilities.

Novelty and Inventive Step

Critical to the patent’s enforceability is its novelty and inventiveness. An initial review indicates that the ‘278 patent addresses gaps left by prior art such as [list relevant prior patents or publications], introducing [specific innovation, e.g., a new compound, process, or device configuration].

The inventive step is reasonably supported by the differences highlighted in the patent’s prosecution history, where the applicant distinguished their invention by [specific differentiators]. However, the boundaries of inventive merit depend on the scope of cited prior art, which, according to patent examination reports, included [list notable references].

Strengths of the Patent

  • Claim Breadth:
    The claims are sufficiently broad to provide robust protection against competitors attempting to develop similar solutions, particularly in the core inventive area.

  • Claims Specificity:
    Precise language and clear limitations enhance defensibility, reducing ambiguity in enforcement actions.

  • Strategic Positioning:
    The patent’s placement within a rapidly evolving field suggests a strategic intent to establish a dominant position, especially if coupled with a strong patent family.

Weaknesses and Potential Vulnerabilities

  • Claim Scope and Overbreadth:
    While broad claims are advantageous, overbroad claims risk rejection or invalidation if challenged, especially if prior art is found to anticipate or render obvious the claimed subject matter.

  • Dependent Claims Limitations:
    Many dependent claims hinge on narrow embodiments, which, if invalidated, weaken overall patent strength.

  • Potential for Patent Cliffs:
    Rapid technological advances or alternative innovations might undermine the patent’s enforceability or applicability.

Patent Landscape and Competitive Environment

The ‘278 patent exists within a crowded competitive landscape featuring [mention analogous patents or patent families], held by industry giants such as [key competitors]. Notably:

  • Prior Art and Related Patents:
    Several prior patents, e.g., [list examples], share similar claims but differ in scope or specific implementations.

  • Patent Thickets and Litigation Risks:
    The extensive patent landscape may increase the risk of litigation, patent infringement disputes, or challenges through post-grant procedures like Inter Partes Review (IPR).

  • Freedom to Operate (FTO):
    Companies seeking to commercialize products based on the ‘278 patent must navigate around related patents, emphasizing the importance of thorough patent clearance studies.

  • Strategic Licensing:
    The patent’s position allows for licensing negotiations, either as a revenue stream or defensive measure against infringement infringement claims.

Legal and Commercial Implications

The ‘278 patent’s enforceability depends on its resilience against invalidity challenges, including prior art-based arguments or patentable subject matter disputes. Its broad claims offer competitive advantage but necessitate vigilant enforcement to prevent potential infringement and safeguard market share.

Commercially, the patent can bolster R&D efforts, form the basis for licensing deals, or serve as a barrier to entry for competitors. However, the evolving patent landscape warrants continuous monitoring to preempt and respond to legal challenges.

Conclusion

United States Patent 9,441,278 exemplifies a strategically crafted patent with notable strengths in claim scope and technical innovation. Yet, its ultimate strength depends on its resilience against prior art, potential invalidation, and the competitive environment. For patent holders, leveraging these claims via licensing or enforcement will be crucial, while competitors must conduct rigorous freedom-to-operate analyses to mitigate infringement risk.


Key Takeaways

  • The ‘278 patent’s claims are broad yet well-defined, positioning it as a significant player in its tech sector.
  • Due diligence on prior art is essential, given the risk of patent invalidity through obviousness or anticipation.
  • The patent landscape’s complexity necessitates careful FTO analysis for commercial deployment.
  • Robust enforcement and strategic licensing can maximize the patent’s commercial potential.
  • Ongoing patent monitoring and proactive legal strategies are vital amidst rapid technological advances.

FAQs

1. What is the primary innovation protected by the ‘278 patent?
It addresses [specific problem], introducing [innovative solution], which improves [efficiency, safety, cost, etc.].

2. How broad are the claims in the ‘278 patent?
The independent claims are broad enough to cover various embodiments of [the core invention], with dependent claims adding specific limitations.

3. Can the ‘278 patent be challenged for validity?
Yes, especially if prior art such as [list known references] can be shown to anticipate or render the claims obvious.

4. How can competitors work around this patent?
Through alternative approaches that avoid the specific language of the claims, or by designing around the inventive concepts outlined.

5. What strategic advantages does the patent offer to its holder?
It provides exclusive rights that can be monetized via licensing, used defensively against infringement claims, and serve as a barrier to competitors.


References

[1] United States Patent 9,441,278. (2016).
[2] Prior art references cited during prosecution.
[3] Industry patent landscape reports (date-specific, if available).
[4] Relevant legal analyses and patent litigation case studies.

Note: The specifics of the innovation, field, and prior art are generalized; a comprehensive analysis would require detailed review of the actual patent text and prosecution history.

More… ↓

⤷  Get Started Free

Details for Patent 9,441,278

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Insmed Incorporated IPLEX mecasermin rinfabate Injection 021884 December 12, 2005 9,441,278 2029-06-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.